#chronicinflammatory

Ulcerative colitis (UC), a chronic inflammatory bowel disease, affects millions worldwide and presents symptoms like abdominal pain, diarrhea, mucous, blood in the stool, and fatigue. Traditional treatments focus on medication and surgery, but acupuncture, an ancient Chinese practice, is increasingly recognized as a complementary therapy. This article explores the potential of acupuncture to alleviate symptoms of ulcerative colitis and improve the quality of life for those living with this condition.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves.

Key Highlight of Chronic Inflammatory Demyelinating Polyneuropathy Market

In 2017, prevalent cases of typical and atypical CIDP in the US varied as 10,342 and 9,936, respectively.

According to DelveInsight estimates, the total prevalent population of CIDP in 7MM was found to be 44,843 in 2017. 

Among the 7MM countries, the United States has a higher population of CIDP.

According to DelveInsight’s analysis, Males are at more at risk to develop CIDP than Females

For more detais on  Chronic Inflammatory Demyelinating Polyneuropathy 

Market visit:

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017” to its report offerings. The report features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297815

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2, 1 and 1 respectively. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment Assessment by Target Assessment by Route of Administration Assessment by Molecule Type

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297815

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/